EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...
Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
Investing.com on MSN15d
Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launchInvesting.com -- Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to Equal Weight and slashed the price target from $285 to $204 ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $275.00. The company’s shares closed yesterday at $164.89. According to ...
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...
Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Biogen (BIIB) with a Peer Perform rating. With a legacy portfolio that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback